GlassScriptPhysician profile
Renae Dorrity
NPI 1629293055
$3,142.53
in general payments reported to CMS, 2019-2025
12 companies · $586 in 2025
The $586 reported for 2025 was more than what a typical Sleep Medicine (Family Medicine) provider received nationally (typical 2025 total: $557).
See the full distribution for Sleep Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41.31 · 2022: $18.26 · 2023: $1,247 · 2024: $1,250 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,934 · Travel and Lodging: $749 · Consulting Fee: $200 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,934.20 |
| Travel and Lodging | $748.78 |
| Consulting Fee | $200.00 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,626.98 | 2023-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $661.05 | 2023-2024 | |
| Zoll Respicardia, INC. | $279.69 | 2024 | Remede System |
| Avadel Cns Pharmaceuticals, LLC | $213.81 | 2025 | Lumryz |
| Harmony Biosciences LLC | $186.89 | 2023-2025 | Wakix |
| Noctrix Health, INC. | $51.66 | 2025 | Nidra |
| Astrazeneca Pharmaceuticals LP | $31.57 | 2021-2022 | |
| Novo Nordisk INC | $28.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $23.30 | 2025 | Dupixent |
| Lilly USA, LLC | $17.79 | 2025 | Zepbound |
| Biocryst US Sales Co., LLC | $16.47 | 2025 | Orladeyo |
| Itamar Medical INC | $5.32 | 2023 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renae Dorrity listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.